4014 a+b domain in type II DNA topoisomerase
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 9 | 5.8 | 1.55× | q = 0.13 | |
| Phenylpropanoids and polyketides | 1 | 0.3 | 4.06× | not tested | |
| Organoheterocyclic compounds | 3 | 1.8 | 1.65× | not tested | |
| Homogeneous non-metal compounds | 4 | 2.6 | 1.57× | not tested | |
| Organic acids and derivatives | 1 | 1.8 | 0.55× | not tested | |
| Nucleosides, nucleotides, and analogues | 1 | 3.3 | 0.31× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00218 | MFX | Moxifloxacin | 5 |
| DB01137 | LFX | Levofloxacin | 4 |
| DB00380 | — | Dexrazoxane | 2 |
| DB00694 | — | Daunorubicin | 2 |
| DB00997 | — | Doxorubicin | 2 |
| DB01643 | DT | Thymidine monophosphate | 2 |
| DB05022 | — | — | 2 |
| DB06362 | — | — | 2 |
| DB06421 | — | — | 2 |
| DB00145 | GLY | Glycine | 1 |
| DB00276 | — | Amsacrine | 1 |
| DB00385 | — | — | 1 |
| DB00444 | — | Teniposide | 1 |
| DB00445 | — | — | 1 |
| DB00467 | — | — | 1 |
| DB00487 | — | — | 1 |
| DB00537 | CPF | Ciprofloxacin | 1 |
| DB00685 | — | Trovafloxacin | 1 |
| DB00978 | — | — | 1 |
| DB01059 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MGmetal | MAGNESIUM ION | 43 |
| NAmetal | SODIUM ION | 15 |
| JK8 | (2~{R})-2-[[5-(2-chlorophenyl)-1,2-benzoxazol-3-yl]oxy]-2-phenyl-ethanamine | 14 |
| MNmetal | MANGANESE (II) ION | 8 |
| CL | CHLORIDE ION | 6 |
| Kmetal | POTASSIUM ION | 6 |
| 8MX | 1-cyclopropyl-6-fluoro-8-methyl-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 4 |
| 94H | ~{N}-[(1~{R})-2-azanyl-1-phenyl-ethyl]-4-(1~{H}-pyrrolo[2,3-b]pyridin-3-yl)thiophene-2-carboxamide | 4 |
| GFN | 1-cyclopropyl-6-fluoro-8-methoxy-7-[(3S)-3-methylpiperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 4 |
| LFX | (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid | 4 |
| MFX | 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 4 |
| CPF | 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID | 3 |
| SM8 | SIMOCYCLINONE D8 | 3 |
| 94K | ~{N}-[(1~{R})-2-azanyl-1-phenyl-ethyl]-5-(2-chlorophenyl)-2-methyl-thiophene-3-carboxamide | 2 |
| ZNmetal | ZINC ION | 2 |
| DT | THYMIDINE-5'-MONOPHOSPHATE | 1 |
| GLY | GLYCINE | 1 |